Alere (ALR) has been under a strong bear grip, hence the stock is down -1.2% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 8.04% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.65% in the last 1 week, and is up 3.12% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 6.6% and the 50-Day Moving Average is 5.83%.
Alere (NYSE:ALR): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $41.57 and $41.55 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $44.10. The buying momentum continued till the end and the stock did not give up its gains. It closed at $43.62, notching a gain of 10.57% for the day. The total traded volume was 5,607,622 . The stock had closed at $39.45 on the previous day.
The company Insiders own 1.93% of Alere shares according to the proxy statements. Institutional Investors own 92.28% of Alere shares. In a related news, The Securities and Exchange Commission has divulged that Flakne Carla, officer (VP, Chief Accounting Officer) of Alere Inc., had unloaded 10,000 shares at an average price of $42.44 in a transaction dated on January 16, 2015. The total value of the transaction was worth $424,400.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time, deliver care, and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G).